Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;21(9):1550-9.
doi: 10.1681/ASN.2009101047. Epub 2010 Jun 24.

Digoxin associates with mortality in ESRD

Affiliations

Digoxin associates with mortality in ESRD

Kevin E Chan et al. J Am Soc Nephrol. 2010 Sep.

Abstract

The safety of prescribing digoxin in ESRD is unknown. Hypokalemia, which frequently occurs among dialysis patients, may enhance the toxicity of digoxin. Here, we analyzed the association between digoxin prescription and survival in a retrospective cohort using covariate- and propensity score-adjusted Cox models to minimize the potential for confounding by indication. Among 120,864 incident hemodialysis patients, digoxin use associated with a 28% increased risk for death (hazard ratio [HR] 1.28; 95% confidence interval 1.25 to 1.31). Increasing serum digoxin level was also significantly associated with mortality (HR 1.19 per ng/ml increase; 95% confidence interval 1.05 to 1.35). This increased mortality risk with level was most pronounced in patients with lower predialysis serum potassium (K) levels (HR 2.53 [P = 0.01] for K <4.3 mEq/L versus HR 0.86 [P = 0.35] for K >4.6 mEq/L). In conclusion, digoxin use among patients who are on hemodialysis associates with increased mortality, especially among those with low predialysis K concentrations.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Crude survival curves show decreased survival with digoxin use. Digoxin users had a statistically significant increased mortality risk when compared with patients who were not prescribed digoxin (P < 0.0001). Among digoxin users, higher serum digoxin levels in the first 90 days of long-term HD were associated with an increased risk for death (P = 0.01, <0.6 versus 0.6 to 0.9 versus 1.0 to 2.2 ng/ml groups).
Figure 2.
Figure 2.
Mortality HRs per 1-ng/ml increase in serum digoxin level stratified by patient characteristics demonstrated a persistent mortality trend in digoxin users. A statistically significant interaction effect existed between K and digoxin level. Models were covariate and propensity score adjusted. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Figure 3.
Figure 3.
The mortality effect associated with a higher serum digoxin level is magnified with decreasing serum K level. Mortality HRs were covariate and propensity score adjusted.

Comment in

Similar articles

Cited by

References

    1. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 336: 525–533, 1997 - PubMed
    1. K/DOQI clinical practice guidelines on cardiovascular disease in dialysis patients: Overview of the epidemiology of cardiovascular disease. Am J Kidney Dis 45: 8–9, 2005 - PubMed
    1. Haji SA, Movahed A: Update on digoxin therapy in congestive heart failure. Am Fam Physician 62: 409–416, 2000 - PubMed
    1. Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O'Neill G, Sharma A, Platia E, Feld GK, Akiyama T, Brodsky MA, Greene HL: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: Approaches to control rate in atrial fibrillation. J Am Coll Cardiol 43: 1201–1208, 2004 - PubMed
    1. Hauptman PJ, Kelly RA: Digitalis. Circulation 99: 1265–1270, 1999 - PubMed